BRISTOL MYERS SQUIBB CO•Financial Summary•AI-Powered Insights

BRISTOL MYERS SQUIBB CO 2026 Q2
Earnings Overview & AI Insights

Detailed performance report for BRISTOL MYERS SQUIBB CO covering Q2 2026. Gain clarity on earnings, revenue trends, and AI-enhanced strategic analysis.

BRISTOL MYERS SQUIBB CO (2026 Q2)

Earnings Performance

No Performance Data

Summary of Financial Performance: Bristol-Myers Squibb delivered a strong Q2 2026, with total revenue up 5% year over year to about $13.0 billion and growth portfolio revenue up 14% to $7.6 billion, now nearly 60% of sales. Key drivers included Eliquis (+21% to ~$4.5 billion), Reblozyl (+29%), Breyanzi (+41%), Camzyos (+59%), Sotyktu (+23%), and Cobenfy (+81%). Gross margin was 71.4%, operating expenses were $4.1 billion, and diluted EPS was $2.04. The company ended the quarter with roughly $11.5 billion in cash and marketable securities, generated $3.4 billion of operating cash flow, and repaid $1.2 billion of debt.

Company Outlook & Strategy: Management raised full-year 2026 revenue and adjusted EPS guidance, citing first-half momentum and a stronger second-half outlook. The company emphasized its transition toward a more durable growth portfolio, continued investment in pipeline and prelaunch activities, and disciplined capital allocation. Strategic priorities remain growth execution, pipeline advancement, business development, and shareholder returns. Management also highlighted a strong financial foundation and optionality to invest in high-value opportunities.

Key Industry Trends: The call reflected continued strength in oncology, immunology, cardiovascular, and neuroscience markets, with BMS seeing strong uptake in products addressing large unmet needs. Management noted evolving standards of care in melanoma, multiple myeloma, hypertrophic cardiomyopathy, and lupus. Broader industry themes included increasing use of AI in drug discovery and development, and a continued focus on differentiated modalities such as ADCs, CELMoDs, and combination therapies.

Operational Highlights: BMS highlighted strong commercial execution across its growth brands and continued portfolio rebalancing away from legacy products. Qvantig is now annualizing above $1 billion, Opdualag remains a strong melanoma franchise, and Camzyos and Sotyktu continue to expand. The company discussed significant pipeline progress, including positive Phase III mezigdomide data, encouraging Iza-bren and pumitamig results, and multiple upcoming pivotal readouts. BMS also announced expanded partnerships with Anthropic and NVIDIA to scale AI capabilities across research and enterprise operations.

Challenges & Risks: Legacy portfolio declines continue to weigh on results, though Eliquis growth offset much of the pressure. Management flagged generic erosion in the legacy portfolio and noted that Opdivo growth was affected by conversion to Qvantig and some wholesale inventory build. Pipeline timing shifted later for milvexian and the ADEPT program due to slower-than-expected event accrual and enrollment, though management framed this as a positive reflection of study quality and event dynamics rather than a setback in confidence.

Key Analyst Questions & Responses: Analysts focused on the delays in the milvexian AFib study and the ADEPT Cobenfy program. Management said both shifts are driven by slower event accrual or enrollment, not by concerns about the underlying science or trial design. For ADEPT, management stressed that trial quality and patient selection remain priorities, and that enrollment-accelerating меры have been implemented. For milvexian, management reiterated that the DSMB/DMC continues to endorse the study and that the later readout simply reflects event timing. Management also signaled confidence in the assets and said the delay could be favorable.

Earnings Call Transcript

Access the official earnings call transcript for BRISTOL-MYERS-SQUIBB-CO 2026 Q2. It provides valuable insights into management commentary, performance drivers, and forward-looking guidance directly from the company.